Provided by Tiger Trade Technology Pte. Ltd.

CSPC PHARMA

9.190
-0.330-3.47%
Volume:135.37M
Turnover:1.24B
Market Cap:105.89B
PE:27.05
High:9.510
Open:9.510
Low:9.015
Close:9.520
52wk High:11.203
52wk Low:6.387
Shares:11.52B
HK Float Shares:11.52B
Volume Ratio:1.02
T/O Rate:1.17%
Dividend:0.30
Dividend Rate:3.31%
EPS(LYR):0.340
ROE:20.90%
ROA:10.70%
PB:2.41
PE(LYR):27.05
PS:2.90

Loading ...

Astrazeneca Azn. Extends Rise to Hit Session High, Last up 6%; Deal with CSPC Pharmaceutical Group Announced Earlier in Day

THOMSON REUTERS
·
Jul 02

Multiple Companies Announce Positive Developments: CSPC Pharma Partners with AstraZeneca, Digital China Wins Major Mobile Server Contract

Deep News
·
Jul 02

CSPC Pharma Begins Tumor Drug Trial in China

MT Newswires Live
·
Jul 02

London's FTSE 100 Rises on Healthcare, Beverages Amid US Jobs Watch

Reuters
·
Jul 02

Market Analysis: Meta's AI Compute Sale Not a Bearish Signal; Healthcare Stocks Surge on Multiple Catalysts

Stock News
·
Jul 02

CSPC Pharma's Tumor Drug Gets Breakthrough Therapy Designation in China

MT Newswires Live
·
Jul 02

CSPC Pharma Gets Marketing Nod for Anemia Drug in China

MT Newswires Live
·
Jul 02

CSPC Pharma Gets China Nod for Trial of Herpes Zoster Vaccine

MT Newswires Live
·
Jul 02

CSPC Pharma Secures NMPA Approval to Launch Clinical Trials for First Recombinant Herpes Zoster Vaccine

Bulletin Express
·
Jul 02

CSPC PHARMA’s ADC Candidate SYS6043 Earns NMPA Breakthrough Therapy Status for Platinum-Resistant Ovarian Cancer

Bulletin Express
·
Jul 02

CSPC PHARMA's In-House Developed SYS6043 Designated as Breakthrough Therapy

Stock News
·
Jul 02

CSPC Pharma's Recombinant Shingles Vaccine Receives Clinical Trial Approval in China

Stock News
·
Jul 02

CSPC Pharmaceutical - Sys6043 Granted Breakthrough Therapy Designation in China for Platinum-resistant Ovarian Cancer

THOMSON REUTERS
·
Jul 02

CSPC Pharmaceutical - Marketing Approval Received from Nmpa

THOMSON REUTERS
·
Jul 02

CSPC Pharmaceutical - Recombinant Herpes Zoster Vaccine (sys6052) Obtains Clinical Trial Approval in China

THOMSON REUTERS
·
Jul 02

CSPC Wins China Clinical Trial Clearance for Recombinant Shingles Vaccine Sys6052

Reuters
·
Jul 02

China's CSPC Pharmaceutical Group to Partner with Astrazeneca for Renal Disease Drug

Reuters
·
Jul 02

CSPC Pharmaceutical - Pharma Enters Collaboration, Option and License Agreement with Astrazeneca for Sirna Drugs

THOMSON REUTERS
·
Jul 02

CSPC Pharmaceutical - Pharma to Receive $30 Mln Upfront, up to $540 Mln Development and $1.2 Bln Sales Milestones

THOMSON REUTERS
·
Jul 02

CSPC Pharmaceutical - Pharma Retains Rights to One Pcc in China

THOMSON REUTERS
·
Jul 02